Nicole A. Grunenberg

Mar 18, 2024 | medrxiv.org | Nathan Erdmann |Wilton B. Williams |Stephen Walsh |Nicole A. Grunenberg

SRW has received institutional funding from the National Institute of Allergy and Infectious Diseases/National Institutes of Health; and institutional grants or contracts from Sanofi Pasteur, Janssen Vaccines/Johnson & Johnson, Moderna Tx, Pfizer, Vir Biotechnology, and Worcester HIV Vaccine; has participated on data safety monitoring or advisory boards for Janssen Vaccines/Johnson & Johnson and BioNTech; and his spouse holds stock/stock options in Regeneron Pharmaceuticals.

Sep 13, 2023 | thelancet.com | Gustavo Dayan |Nadine Rouphael |Stephen Walsh |Nicole A. Grunenberg

Research in context Evidence before this study We searched PubMed from database inception to Dec 20, 2022, with no language restrictions, for studies reporting the efficacy or effectiveness of vaccines against emergent SARS-CoV-2 variants, including omicron (B.1.1.529), using the search terms “vaccine”, “efficacy OR effectiveness”, “SARS-CoV-2”, “omicron OR variant of concern OR emerging variant”, and “clinical trial”, and for studies reporting data from updated or bivalent vaccine candidates...